# British Journal of Anaesthesia - 2025å¹´12æœˆ é‡é»æ–‡ç« æ‘˜è¦

> æ•´ç†æ—¥æœŸï¼š2025-12-15

---

## 1. DAS 2025 å›°é›£æ°£é“æŒ‡å¼•

**Difficult Airway Society 2025 guidelines for tracheal intubation: thoughtful preparation for success and systematic management of failure**

- **ä½œè€…**: Jagannathan N, Aziz MF
- **PMID**: 41339170
- **DOI**: [10.1016/j.bja.2025.11.003](https://doi.org/10.1016/j.bja.2025.11.003)
- **é¡å‹**: Editorial

### æ‘˜è¦

DAS 2025 æ°£ç®¡æ’ç®¡æŒ‡å¼•ä»£è¡¨äº†å¾ã€Œæ•‘æ´å°å‘ã€æ°£é“ç­–ç•¥è½‰è®Šç‚ºã€Œé¦–æ¬¡æˆåŠŸã€å’Œã€Œä¸»å‹•é é˜²å¤±æ•—ã€çš„é‡å¤§å…¸ç¯„è½‰ç§»ã€‚

**é—œéµæ›´æ–°åŒ…æ‹¬ï¼š**
- **é¦–é¸è¦–é »å–‰é¡ (Videolaryngoscopy)** - ä½œç‚ºç¬¬ä¸€ç·šå·¥å…·
- **æ›´æ—©çµ¦äºˆè‚Œè‚‰é¬†å¼›åŠ‘** - æå‡æ’ç®¡æˆåŠŸç‡
- **ä¿®è¨‚ç‰ˆ ABCD æ°£é“æ•‘æ´æ–¹æ³•**
- **æ¨™æº–åŒ–å‚ç›´åˆ‡é–‹ç·Šæ€¥é ¸å‰å…¥è·¯ (Emergency Front-of-Neck Access)**

æœ¬ç¯‡ç¤¾è«–å¼·èª¿äº† 2025 å¹´æ›´æ–°ä¸­çš„é—œéµå…¸ç¯„è½‰ç§»ï¼Œæ¢è¨å…¶åŸç†å’Œå¯¦æ–½çš„å¯¦éš›æŒ‘æˆ°ã€‚

### åŸæ–‡æ‘˜è¦ (Original Abstract)

> The DAS 2025 tracheal intubation guidelines represent a shift from rescue-based airway strategies to a focus on first-attempt success and proactive prevention of failure. Key updates include first-line videolaryngoscopy, earlier neuromuscular block, a revised ABCD approach to airway rescue, and standardised vertical-incision emergency front-of-neck access. This editorial highlights the key paradigm shifts in the 2025 update, exploring both their rationale and the practical challenges to implementation.

### ç›¸é—œæŒ‡å¼•æ–‡ç»

- **å®Œæ•´æŒ‡å¼•**: Ahmad I, El-Boghdadly K, et al. *Difficult Airway Society 2025 guidelines for management of unanticipated difficult tracheal intubation in adults.* Br J Anaesth. 2025 Nov 7. PMID: 41203471

**é—œéµè©**: airway management, clinical guidelines, difficult airway, oxygenation, patient safety, tracheal intubation

---

## 2. TAP Block ç³»çµ±æ€§å›é¡§èˆ‡çµ±åˆåˆ†æ

**Transversus abdominis plane block for postoperative pain management and opioid sparing: a systematic review and meta-analysis of randomised controlled trials**

- **ä½œè€…**: Zako J, Kevorkov A, Jeffries SD, et al.
- **PMID**: 41339171
- **DOI**: [10.1016/j.bja.2025.10.033](https://doi.org/10.1016/j.bja.2025.10.033)
- **é¡å‹**: Systematic Review & Meta-analysis
- **è¨»å†Š**: PROSPERO (CRD42024374067)

### æ‘˜è¦

#### èƒŒæ™¯
è…¹æ©«è‚Œå¹³é¢é˜»æ»¯ (TAP block) æ˜¯ä¸€ç¨®å€åŸŸéº»é†‰æŠ€è¡“ï¼Œé‡å°èƒ¸è…°æ¤æ„Ÿè¦ºç¥ç¶“å‚³å…¥çº–ç¶­ï¼Œç‚ºå‰å¤–å´è…¹å£æä¾›é®ç—›ã€‚

#### æ–¹æ³•
- æœç´¢ MEDLINEã€Embase å’Œ Cochrane CENTRALï¼ˆå¾å»ºåº«è‡³ 2024 å¹´ 5 æœˆï¼‰
- ç´å…¥æ¯”è¼ƒ TAP block èˆ‡å®‰æ…°åŠ‘ã€å±€éƒ¨æµ¸æ½¤ã€ç¡¬è†œå¤–é®ç—›æˆ–é˜å…§å—å•¡çš„ RCT
- å ±å‘Š 6ã€12 æˆ– 24 å°æ™‚è¡“å¾Œç–¼ç—›è©•åˆ†æˆ–ç´¯ç© 24 å°æ™‚å—å•¡æ¶ˆè€—é‡

#### çµæœ
å…±ç´å…¥ **123 å€‹ RCT**ã€‚

**èˆ‡å®‰æ…°åŠ‘æ¯”è¼ƒ**ï¼šTAP block çµ„æ‰€æœ‰æŒ‡æ¨™å‡é¡¯è‘—é™ä½

**èˆ‡å±€éƒ¨æµ¸æ½¤æ¯”è¼ƒ**ï¼š
| æŒ‡æ¨™ | SMD | 95% CI | P å€¼ |
|------|-----|--------|------|
| 6h ç–¼ç—› | -0.89 | -1.35 to -0.43 | <0.001 |
| 12h ç–¼ç—› | -1.27 | -2.08 to -0.46 | 0.002 |
| 24h ç–¼ç—› | -0.66 | -1.01 to -0.32 | <0.001 |
| 24h å—å•¡æ¶ˆè€— | -0.99 | -1.52 to -0.47 | <0.001 |

**èˆ‡ç¡¬è†œå¤–æ¯”è¼ƒ**ï¼šåƒ… 12h ç–¼ç—›è©•åˆ†æœ‰é¡¯è‘—é™ä½

**èˆ‡é˜å…§å—å•¡æ¯”è¼ƒ**ï¼šç„¡é¡¯è‘—å·®ç•°

#### çµè«–
**TAP block æ˜¯è…¹éƒ¨æ‰‹è¡“å¾Œç–¼ç—›ç®¡ç†å’Œç¯€çœé´‰ç‰‡é¡è—¥ç‰©çš„æœ‰æ•ˆéº»é†‰æ–¹å¼ã€‚**

### åŸæ–‡æ‘˜è¦ (Original Abstract)

> **Background:** Transversus abdominis plane (TAP) block is a regional anaesthesia technique that targets thoracolumbar sensory afferents to provide analgesia to the anterolateral abdominal wall.
>
> **Methods:** A search of MEDLINE, Embase, and Cochrane CENTRAL was performed from inception until May 2024, to identify randomised controlled trials (RCTs) comparing TAP block with placebo, local infiltration, epidural analgesia, or intrathecal morphine, that reported postoperative pain scores at 6, 12, or 24 h, or cumulative 24-h morphine consumption.
>
> **Results:** In 123 RCTs, TAP block, compared with placebo, significantly decreased pain scores at 6 h (standard mean difference [SMD] -1.45, 95% confidence interval [CI] -1.84 to -1.06, P<0.001), 12 h (SMD -1.41, 95% CI -1.82 to -1.00, P<0.001), and 24 h (SMD -1.31, 95% CI -1.67 to -0.95, P<0.001), and 24-h cumulative morphine consumption (SMD -1.18, 95% CI -1.56 to -0.80, P<0.001). Compared with local infiltration, TAP block significantly decreased pain scores at 6 h (SMD -0.89, 95% CI -1.35 to -0.43, P<0.001), 12 h (SMD -1.27, 95% CI -2.08 to -0.46, P=0.002), and 24 h (SMD -0.66, 95% CI -1.01 to -0.32, P<0.001), and 24-h cumulative morphine consumption (SMD -0.99, 95% CI -1.52 to -0.47, P<0.001). Compared with epidural analgesia, TAP block significantly decreased pain scores at only 12 h (SMD -0.64, 95% CI -1.27 to -0.01, P=0.047). Compared with intrathecal morphine, there was no significant difference between groups.
>
> **Conclusions:** TAP block is an effective analgesic technique for postoperative pain management and opioid sparing after abdominal surgery.

### è‡¨åºŠå¯¦å‹™è¦é»

1. **TAP block å„ªæ–¼å®‰æ…°åŠ‘**: åœ¨æ‰€æœ‰æ™‚é–“é» (6h, 12h, 24h) éƒ½èƒ½é¡¯è‘—é™ä½ç–¼ç—›åˆ†æ•¸å’Œå—å•¡æ¶ˆè€—
2. **TAP block å„ªæ–¼å±€éƒ¨æµ¸æ½¤**: æ•ˆæœé¡¯è‘—å„ªæ–¼å‚·å£å±€éƒ¨æµ¸æ½¤éº»é†‰
3. **TAP block vs ç¡¬è†œå¤–**: åƒ…åœ¨ 12 å°æ™‚æœ‰å„ªå‹¢ï¼Œä½†å¯é¿å…ç¡¬è†œå¤–ç›¸é—œä½µç™¼ç—‡
4. **TAP block vs é˜å…§å—å•¡**: æ•ˆæœç›¸ç•¶ï¼Œä½†å‰¯ä½œç”¨æ¨¡å¼ä¸åŒ

**é—œéµè©**: TAP block, analgesia, opioids, pain, systematic review

---

## 3. éº»é†‰æ™‚é–“é æ¸¬å› å­çš„çµ±è¨ˆæ–¹æ³•å­¸ç ”ç©¶

**Controlling familywise error rates and false discovery rates when studying predictors of log-normal durations in anaesthesia: a simulation study using generalised linear modelling**

- **ä½œè€…**: Chen PF, Dexter F
- **PMID**: 41339172
- **DOI**: [10.1016/j.bja.2025.09.054](https://doi.org/10.1016/j.bja.2025.09.054)
- **é¡å‹**: Simulation Study

### æ‘˜è¦

#### èƒŒæ™¯
éº»é†‰å­¸ç ”ç©¶ç¶“å¸¸ä½¿ç”¨å»£ç¾©ç·šæ€§æ¨¡å‹ (GLM) ä¾†è­˜åˆ¥å°æ•¸æ­£æ…‹åˆ†å¸ƒçµæœçš„ã€Œç¨ç«‹é æ¸¬å› å­ã€ï¼ˆå¦‚æ‰‹è¡“å’Œéº»é†‰æ™‚é–“ï¼‰ã€‚ç„¶è€Œï¼Œå¸¸è¦‹çš„å¤šé‡æ¯”è¼ƒæ ¡æ­£æ–¹æ³•åœ¨é˜²æ­¢ I é¡å’Œ II é¡éŒ¯èª¤æ–¹é¢çš„è¡¨ç¾å°šä¸æ¸…æ¥šã€‚

#### æ–¹æ³•
é€²è¡Œè’™åœ°å¡ç¾…æ¨¡æ“¬ï¼Œè©•ä¼°æ§åˆ¶æ—ç³»éŒ¯èª¤ç‡ (FWER) å’ŒéŒ¯èª¤ç™¼ç¾ç‡ (FDR) çš„æ–¹æ³•ï¼š
- **FWER æ–¹æ³•**: Bonferroniã€Å idÃ¡kã€Holm-Bonferroniã€Hochberg
- **FDR æ–¹æ³•**: Benjamini-Hochbergã€Benjamini-Yekutieli

æ¨¡æ“¬æ•¸æ“šé›†å…·æœ‰å°æ•¸æ­£æ…‹çµæœå’Œä¸‰å€‹äºŒå…ƒé æ¸¬è®Šé‡ï¼Œé æ¸¬è®Šé‡é–“çš„ç›¸é—œæ€§å„ç•°ã€‚

#### çµæœ
| æ–¹æ³• | FWER (æ‡‰ç‚º 5%) | å‚™è¨» |
|------|----------------|------|
| ç„¡æ ¡æ­£ | 12.6-14.8% | âŒ éé«˜ |
| **Bonferroni** | **5.2-5.3%** | âœ… æœ€æº–ç¢º |

å°æ–¼ FDR æ§åˆ¶ï¼š
- **Benjamini-Yekutieli**: ç¨ç«‹å’Œè² ç›¸é—œé æ¸¬å› å­æœ‰æ•ˆ (4.5-5.1%)
- ä½†åœ¨å¼·æ­£ç›¸é—œé æ¸¬å› å­ä¸‹å¤±æ•ˆ (6.0-9.5%)

#### çµè«–
1. ä½¿ç”¨ GLM è­˜åˆ¥å°æ•¸æ­£æ…‹çµæœçš„é æ¸¬å› å­æ™‚ï¼Œ**æœ€ç°¡å–®çš„ Bonferroni æ ¡æ­£** æä¾›äº†å¯é çš„ FWER æ§åˆ¶
2. Benjamini-Yekutieli æœ€é©åˆæ§åˆ¶ FDRï¼Œä½†ç•¶é æ¸¬å› å­æ­£ç›¸é—œæ™‚å¯èƒ½ä¸å¯é 

### åŸæ–‡æ‘˜è¦ (Original Abstract)

> **Background:** Anaesthesiology research often uses generalised linear models (GLMs) to identify "independent predictors" of log-normal outcomes (e.g. surgical case and anaesthesia durations). However, how well common methods of multiple comparison correction perform in preventing Type I and Type II errors is unclear.
>
> **Methods:** We performed Monte Carlo simulations to evaluate methods for controlling the familywise error rate (FWER): Bonferroni, Å idÃ¡k, Holm-Bonferroni, Hochberg; and the false discovery rate (FDR): Benjamini-Hochberg, Benjamini-Yekutieli. Simulated data sets had log-normal outcomes and three binary predictors with varying inter-predictor correlations.
>
> **Results:** The proportion of simulations with â‰¥1 significant result among 3 truly non-significant predictors was similar among FWER methods: Bonferroni, Å idÃ¡k, Holm-Bonferroni, and Hochberg (4.7-5.5% for correlated predictors). Without correction, this proportion (12.6-14.8%) exceeded 5%. When only 1 of 3 predictors was significant, power to detect it was equivalent among correction methods (88.5-89.4%). Across all predictor correlations, Benjamini-Yekutieli provided reliable FDR control (4.5-5.1% when no predictors significant, 2.6-2.9% when 1 significant). Benjamini-Hochberg controlled FDR for independent (3.8-4.0%) and negatively correlated (4.5-5.0%) predictors but not for strong positive correlations (6.0-9.5%).
>
> **Conclusions:** When using GLMs to identify predictors of log-normal outcomes, the simplest Bonferroni correction provides reliable FWER control with minimal loss of power. Benjamini-Yekutieli is best suited for FDR control but may be unreliable when predictors are positively correlated.

### ç ”ç©¶æ–¹æ³•å­¸è¦é»

1. **è’™åœ°å¡ç¾…æ¨¡æ“¬è¨­è¨ˆ**: ä½¿ç”¨ä¸‰å€‹äºŒå…ƒé æ¸¬è®Šé‡ï¼Œæ¸¬è©¦ä¸åŒé æ¸¬è®Šé‡é–“ç›¸é—œæ€§çš„æƒ…å¢ƒ
2. **å¤šé‡æ¯”è¼ƒå•é¡Œ**: æœªæ ¡æ­£æ™‚ï¼Œfalse positive rate é«˜é” 12.6-14.8%ï¼ˆæ‡‰ç‚º 5%ï¼‰
3. **çµ±è¨ˆæª¢å®šåŠ›**: æ‰€æœ‰æ ¡æ­£æ–¹æ³•çš„æª¢å®šåŠ›ç›¸ç•¶ (88.5-89.4%)ï¼Œè¡¨ç¤º Bonferroni ä¸¦ééåº¦ä¿å®ˆ

### è‡¨åºŠç ”ç©¶å»ºè­°

| æƒ…å¢ƒ | å»ºè­°æ–¹æ³• |
|------|----------|
| æ§åˆ¶ FWERï¼ˆé¿å…ä»»ä½• false positiveï¼‰| **Bonferroni** |
| æ§åˆ¶ FDRï¼ˆå®¹è¨±å°‘é‡ false positiveï¼‰| Benjamini-Yekutieli |
| é æ¸¬å› å­æ­£ç›¸é—œ | é¿å…ä½¿ç”¨ Benjamini-Hochberg |

**é—œéµè©**: Monte Carlo simulation, familywise error rate, false discovery rate, generalised linear model, log-normal distribution, multiple comparisons

---

## 4. PRINCE è©¦é©—ï¼šé ç«¯ç¼ºè¡€é è™•ç†åœ¨éå¿ƒè‡Ÿæ‰‹è¡“ä¸­çš„æ•ˆæœ

**The PRINCE trial of remote ischaemic preconditioning in noncardiac surgery to reduce myocardial injury: sign o' the times**

- **ä½œè€…**: Ackland GL, Pinto BB
- **PMID**: 41350217
- **DOI**: [10.1016/j.bja.2025.11.005](https://doi.org/10.1016/j.bja.2025.11.005)
- **é¡å‹**: Editorial

### æ‘˜è¦

#### PRINCE è©¦é©—æ¦‚è¿°
- **è¨­è¨ˆ**: å¤šåœ‹ã€é›™ç›²ã€éš¨æ©Ÿå°ç…§è©¦é©—
- **æ¨£æœ¬é‡**: 1213 ä½æ¥å—éå¿ƒè‡Ÿæ‰‹è¡“çš„æ‚£è€…
- **ä»‹å…¥**: å…¨èº«éº»é†‰å¾Œã€æ‰‹è¡“å‰æ¥å—é ç«¯ç¼ºè¡€é è™•ç† (RIPC) æˆ–å‡ RIPC

#### çµæœ
| çµ„åˆ¥ | è¡“å¾Œå¿ƒè‚Œæå‚·ç™¼ç”Ÿç‡ |
|------|-------------------|
| RIPC çµ„ | 215/566 (38.0%) |
| å‡ RIPC çµ„ | 223/596 (37.4%) |

**ä¸»è¦ç™¼ç¾ï¼šRIPC èˆ‡å‡ RIPC ä¹‹é–“ç„¡é¡¯è‘—å·®ç•°**

#### è¨è«–
PRINCE è©¦é©—å¢æ·»äº†åœè¡“æœŸé†«å­¸ä¸­ RIPC ä½œç”¨çš„çœ‹ä¼¼çŸ›ç›¾çš„æ–‡ç»ã€‚ä½œè€…è¨è«–äº†è§£é‡‹é€™äº›å·®ç•°çš„è©¦é©—ç‰¹å®šåŸå› å’Œæ©Ÿåˆ¶åŸå› ï¼Œä¸¦èªç‚º **RIPC åœ¨æ¸›å°‘éå¿ƒè‡Ÿæ‰‹è¡“å™¨å®˜æå‚·æ–¹é¢çš„ä½œç”¨ä»æœ‰å¯èƒ½**ã€‚

### åŸæ–‡æ‘˜è¦ (Original Abstract)

> The PRINCE trial tested remote ischaemic preconditioning (RIPC) for prevention of myocardial injury after noncardiac surgery. This multicentre, double-blind, RCT randomised 1213 patients undergoing noncardiac surgery to receive RIPC or sham-RIPC after induction of general anaesthesia and before surgery. The primary outcome was myocardial injury (peak high-sensitivity cardiac troponin T â‰¥20 ng/L) within 3 days of surgery.
>
> Results: There was no significant difference between RIPC (215 of 566 patients, 38.0%) and sham-RIPC (223 of 596 patients, 37.4%). The PRINCE trial adds to the seemingly contradictory literature on the role of RIPC in perioperative medicine. We discuss both trial-specific and mechanistic reasons that may explain these discrepancies, and argue that a role for RIPC in reducing organ damage during noncardiac surgery remains possible.

### RIPC åœ¨éå¿ƒè‡Ÿæ‰‹è¡“çš„è­‰æ“šå›é¡§

| è©¦é©— | çµæœ | è§£è®€ |
|------|------|------|
| PRINCE (2025) | é™°æ€§ | ä¸»è¦çµ‚é»ç„¡å·®ç•° |
| å…ˆå‰ meta-analysis | æ­£é¢ | å¿ƒè‡Ÿæ‰‹è¡“æœ‰æ•ˆ |
| æ©Ÿåˆ¶ç ”ç©¶ | æ”¯æŒ | å‹•ç‰©æ¨¡å‹é¡¯ç¤ºä¿è­·æ•ˆæœ |

### ç‚ºä½• PRINCE è©¦é©—ç‚ºé™°æ€§ï¼Ÿå¯èƒ½åŸå› 

1. **RIPC æ™‚æ©Ÿ**: å…¨éº»èª˜å°å¾ŒåŸ·è¡Œï¼Œå¯èƒ½å½±éŸ¿ä¿¡è™Ÿè½‰å°
2. **æ‚£è€…æ—ç¾¤**: éå¿ƒè‡Ÿæ‰‹è¡“é¢¨éšªè¼ƒä½
3. **èƒŒæ™¯ç™‚æ³•**: ç¾ä»£åœè¡“æœŸç…§è­·å·²å¾ˆå®Œå–„
4. **troponin é–€æª»**: 20 ng/L æ˜¯å¦ç‚ºæœ€ä½³åˆ‡é»ï¼Ÿ

### æœªä¾†ç ”ç©¶æ–¹å‘

> *"A role for RIPC in reducing organ damage during noncardiac surgery remains possible."*

ä½œè€…èªç‚ºæ‡‰é€²ä¸€æ­¥ç ”ç©¶ï¼š
- RIPC çš„æœ€ä½³æ™‚æ©Ÿå’ŒåŠ‘é‡
- é«˜é¢¨éšªæ‚£è€…äºç¾¤
- åˆä½µå…¶ä»–å™¨å®˜ä¿è­·ç­–ç•¥

**é—œéµè©**: autonomic, myocardial injury, noncardiac surgery, perioperative care, remote ischaemic preconditioning

---

## 5. æƒ¡æ€§é«˜ç†± RYR1 åŸºå› è®Šç•°åŠŸèƒ½åˆ†æ

**Functional analysis of RYR1 variants in Australian and New Zealand patients at risk of susceptibility to malignant hyperthermia**

- **ä½œè€…**: Schiemann AH, Burling SM, Allen R, et al.
- **PMID**: 41339169
- **DOI**: [10.1016/j.bja.2025.10.025](https://doi.org/10.1016/j.bja.2025.10.025)
- **é¡å‹**: Original Research

### æ‘˜è¦

#### èƒŒæ™¯
è‚Œè‚‰æ´»æª¢å’Œé«”å¤–æ”¶ç¸®æ¸¬è©¦ (IVCT) ä»æ˜¯æƒ¡æ€§é«˜ç†± (MH) æ˜“æ„Ÿæ€§ç—‡ç‹€å‰è¨ºæ–·çš„é‡‘æ¨™æº–ã€‚ç•¶å®¶æ—è®Šç•°è¢«åˆ†é¡ç‚ºè‡´ç—…æ€§æˆ–å¯èƒ½è‡´ç—…æ€§æ™‚ï¼Œå¯ä½¿ç”¨ DNA åˆ†æã€‚è®Šç•°å¿…é ˆæ»¿è¶³ä¸€ç³»åˆ—æ¨™æº–ï¼Œå…¶ä¸­ä¹‹ä¸€æ˜¯åœ¨æ‰¹å‡†çš„ç³»çµ±ä¸­é€²è¡ŒåŠŸèƒ½åˆ†æï¼Œè­‰æ˜æš´éœ²æ–¼é©ç•¶æ¿€å‹•åŠ‘æ™‚éˆ£é‡‹æ”¾çš„è¶…æ•æ€§ã€‚

#### æ–¹æ³•
1. å° 7 åæœ‰ MH è‡¨åºŠç—…å²çš„æ‚£è€…é€²è¡Œ RYR1 è®Šç•°ç¯©æŸ¥ï¼ˆæ“´å¢å­æˆ–å…¨å¤–é¡¯å­æ¸¬åºï¼‰
2. å°‡ 6 å€‹ RYR1 è®Šç•°å¼•å…¥ç·¨ç¢¼äººé¡ ryanodine å—é«”çš„ cDNA
3. åœ¨äººèƒšèƒè…ç´°èƒä¸­æ¸¬è©¦å…¶å° 4-æ°¯é–“ç”²é…šéŸ¿æ‡‰çš„éˆ£é‡‹æ”¾æ•ˆæ‡‰
4. ä½¿ç”¨ EMHG è©•åˆ†çŸ©é™£å’Œ ClinGen RYR1 è®Šç•°å°ˆå®¶å°çµ„æŒ‡å—é€²è¡Œè¨ˆç®—æ©Ÿè©•ä¼°

#### çµæœ

| è®Šç•° | å° 4-æ°¯é–“ç”²é…šæ•æ„Ÿæ€§ | åˆ†é¡æ›´æ–° |
|------|---------------------|----------|
| p.Gln464Lys | âœ… è¶…æ• | â†’ è‡´ç—…æ€§ |
| p.Asp2431Val | âœ… è¶…æ• | â†’ è‡´ç—…æ€§ |
| p.Val2354Met | âœ… è¶…æ• | â†’ è‡´ç—…æ€§ |
| p.Val2627Leu | âœ… è¶…æ• | â†’ è‡´ç—…æ€§ |
| p.Pro4973Leu | âœ… è¶…æ• | å¯èƒ½è‡´ç—… â†’ è‡´ç—…æ€§ |
| p.Ser2542Asn | âœ… è¶…æ• | ä»ç‚ºã€Œæ„ç¾©ä¸æ˜ã€ |

#### çµè«–
- **4 å€‹é¡å¤–çš„ RYR1 è®Šç•°**å¯æ·»åŠ åˆ° EMHG ç®¡ç†çš„ RYR1 ç–¾ç—…ç›¸é—œè®Šç•°åˆ—è¡¨ä¸­ï¼Œæœªä¾†å¯ç”¨æ–¼è¨ºæ–·
- **1 å€‹è®Šç•°**å¾å¯èƒ½è‡´ç—…å‡ç´šç‚ºè‡´ç—…æ€§
- **1 å€‹è®Šç•°**ä»ç‚ºæ„ç¾©ä¸æ˜è®Šç•°

### åŸæ–‡æ‘˜è¦ (Original Abstract)

> **Background:** Muscle biopsy and in vitro contracture testing (IVCT) remain the reference method for presymptomatic diagnosis of malignant hyperthermia (MH) susceptibility. DNA analysis may be used when the familial variant is classified as pathogenic or likely pathogenic. Variants must fulfil a series of criteria, one of which is functional analysis in an approved system that demonstrates hypersensitivity of calcium release upon exposure to appropriate agonist.
>
> **Methods:** Seven patients with a clinical history of MH were screened for RYR1 variants by amplicon or whole-exome sequencing. Six RYR1 variants were introduced into a cDNA encoding the human ryanodine receptor and tested for their effect on calcium release in response to 4-chloro-m-cresol in human embryonic kidney cells. In silico assessment was performed using the EMHG scoring matrix and ClinGen RYR1 Variant Expert Panel guidelines.
>
> **Results:** All six variants displayed hypersensitivity to 4-chloro-m-cresol (EC50 significantly lower than wild-type). Combined in silico and functional evidence reclassified four variants as pathogenic (p.Gln464Lys, p.Asp2431Val, p.Val2354Met, p.Val2627Leu), upgraded one from likely pathogenic to pathogenic (p.Pro4973Leu), and one remained as a variant of uncertain significance (p.Ser2542Asn).
>
> **Conclusions:** Four additional RYR1 variants can be added to the EMHG-curated list of RYR1 disease-associated variants for future diagnostic use in families carrying these variants. One variant was upgraded from likely pathogenic to pathogenic. One variant remains as a variant of uncertain significance owing to lack of evidence of independent incidence.

### åŠŸèƒ½åˆ†ææ–¹æ³•è©³è§£

**4-æ°¯é–“ç”²é…š (4-CmC) æ¸¬è©¦åŸç†**:
- 4-CmC æ˜¯ ryanodine å—é«”çš„æ¿€å‹•åŠ‘
- æ¸¬é‡ EC50ï¼ˆåŠæœ€å¤§æœ‰æ•ˆæ¿ƒåº¦ï¼‰
- MH ç›¸é—œè®Šç•°æœƒé¡¯ç¤º EC50 é¡¯è‘—ä½æ–¼é‡ç”Ÿå‹ï¼ˆè¶…æ•åæ‡‰ï¼‰

**EMHG è©•åˆ†ç³»çµ±**:
- European Malignant Hyperthermia Group åˆ¶å®šçš„è©•åˆ†çŸ©é™£
- çµåˆè‡¨åºŠã€åŠŸèƒ½ã€è¨ˆç®—æ©Ÿé æ¸¬è­‰æ“š
- ç”¨æ–¼è®Šç•°åˆ†é¡ï¼šPathogenic / Likely Pathogenic / VUS / Likely Benign / Benign

### è‡¨åºŠæ„ç¾©

1. **æ“´å¤§è¨ºæ–·æ€§åŸºå› æª¢æ¸¬**: 4 å€‹æ–°è®Šç•°å¯ç”¨æ–¼å®¶æ—ç¯©æŸ¥ï¼Œé¿å…ä¾µå…¥æ€§è‚Œè‚‰æ´»æª¢
2. **ç²¾æº–é†«ç™‚æ‡‰ç”¨**: å·²çŸ¥è®Šç•°çš„å®¶æ—æˆå“¡å¯ç›´æ¥é€²è¡Œ DNA æª¢æ¸¬
3. **VUS è™•ç†**: p.Ser2542Asn åŠŸèƒ½ç•°å¸¸ä½†ç¼ºä¹ç¨ç«‹ç™¼ç”Ÿè­‰æ“šï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶

### æ¾³ç´åœ°å€ MH ç ”ç©¶ç¶²çµ¡

æœ¬ç ”ç©¶ä¾†è‡ª **æ¾³æ´²å’Œç´è¥¿è˜­ MH ç ”ç©¶ç¶²çµ¡**ï¼Œå¼·èª¿äº†åœ‹éš›åˆä½œåœ¨ç½•è¦‹ç–¾ç—…ç ”ç©¶ä¸­çš„é‡è¦æ€§ã€‚

**é—œéµè©**: calcium release, malignant hyperthermia, pathogenicity, presymptomatic diagnosis, ryanodine receptor

---

## ç¸½çµ

| # | ä¸»é¡Œ | é¡å‹ | è‡¨åºŠé‡è¦æ€§ |
|---|------|------|-----------|
| 1 | DAS 2025 å›°é›£æ°£é“æŒ‡å¼• | æŒ‡å—è©•è«– | â­â­â­â­â­ |
| 2 | TAP Block Meta-analysis | ç³»çµ±å›é¡§ | â­â­â­â­â­ |
| 3 | çµ±è¨ˆæ–¹æ³•å­¸ (Bonferroni) | æ¨¡æ“¬ç ”ç©¶ | â­â­â­ |
| 4 | PRINCE è©¦é©— (RIPC) | è©¦é©—è©•è«– | â­â­â­â­ |
| 5 | æƒ¡æ€§é«˜ç†± RYR1 è®Šç•° | åŸå‰µç ”ç©¶ | â­â­â­â­ |

## æœ¬æœˆé‡é»æ•´ç†

### ğŸ¯ è‡¨åºŠå¯¦å‹™æ”¹è®Š

1. **æ°£é“ç®¡ç†**: DAS 2025 æŒ‡å¼•å»ºè­°è¦–é »å–‰é¡ä½œç‚ºç¬¬ä¸€ç·šå·¥å…·ï¼Œå¼·èª¿ã€Œé¦–æ¬¡æˆåŠŸã€ç­–ç•¥
2. **è¡“å¾Œé®ç—›**: TAP block é¡¯è‘—å„ªæ–¼å±€éƒ¨æµ¸æ½¤éº»é†‰ï¼Œæ˜¯è…¹éƒ¨æ‰‹è¡“å¾Œçš„æœ‰æ•ˆé¸æ“‡
3. **æƒ¡æ€§é«˜ç†±ç¯©æŸ¥**: 4 å€‹æ–°çš„ RYR1 è‡´ç—…æ€§è®Šç•°å¯ç”¨æ–¼å®¶æ—åŸºå› æª¢æ¸¬

### ğŸ“Š ç ”ç©¶æ–¹æ³•å­¸å•Ÿç¤º

- å¤šé‡æ¯”è¼ƒæ ¡æ­£ï¼š**Bonferroni** åœ¨éº»é†‰ç ”ç©¶çš„ GLM åˆ†æä¸­ä»ç„¶å¯é 
- RIPC ç ”ç©¶ï¼šå³ä½¿å¤§å‹ RCT çµæœç‚ºé™°æ€§ï¼Œæ©Ÿåˆ¶ç ”ç©¶ä»æ”¯æŒé€²ä¸€æ­¥æ¢ç´¢

### ğŸ”¬ å¾…è§£æ±ºå•é¡Œ

1. RIPC åœ¨éå¿ƒè‡Ÿæ‰‹è¡“çš„æœ€ä½³æ‡‰ç”¨æ™‚æ©Ÿå’Œæ‚£è€…æ—ç¾¤
2. RYR1 VUS è®Šç•°çš„é€²ä¸€æ­¥åŠŸèƒ½é©—è­‰
3. TAP block æŠ€è¡“å’Œæ™‚æ©Ÿçš„å„ªåŒ–

---

## ç›¸é—œé€£çµ

- [British Journal of Anaesthesia](https://www.bjanaesthesia.org/)
- [DAS Guidelines](https://das.uk.com/)
- [EMHG - European Malignant Hyperthermia Group](https://www.emhg.org/)

---

*Generated by AI Assistant with PubMed Search MCP*
*Last Updated: 2025-12-15*
